RALEIGH, N.C., May 22, 2017 -- PRA Health Sciences, Inc., (PRA) (NASDAQ:PRAH) is pleased to announce that for the fourth consecutive year it was recognized as the International Clinical Research Company of the Year. PRA received the award at a PharmaTimes ceremony in London. This award follows PRA’s recent recognition as Clinical Research Company of the Year in the PharmaTimes Americas competition.
|
|||||
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/29ac9b83-70bf-451e-a05f-bda1b8a05df8
“PRA is honored to once again receive this prestigious award,” said David Passov, Senior Vice President, Project Management EAPA. “It is recognition of our talented and dedicated employees and their passion to help others through their clinical development work.”
PRA won a total of three Gold, four Silver and five Bronze awards. Individual gold award recipients include:
- Clinical Trial Administrator of the Year: James Battisti
- Project Manager of the Year: Caroline Cattelin
Organized by PharmaTimes, the annual International Clinical Researcher of the Year competition provides a unique opportunity for clinical researchers from all over the world to benchmark their competencies and skills against their peers in an international learning environment. Designed and judged by an independent steering committee of high-level industry leaders, the International Clinical Researcher of the Year has categories for clinical researchers and teams at all stages of their career.
ABOUT PRA HEALTH SCIENCES
PRA (NASDAQ: PRAH) is one of the world’s leading global CROs by revenue, providing outsourced clinical development services to the biotechnology and pharmaceutical industries. PRA’s global clinical development platform includes more than 70 offices across North America, Europe, Asia, Latin America, South Africa, Australia and the Middle East and over 13,300 employees worldwide. Since 2000, PRA has performed approximately 3,500 clinical trials worldwide. In addition, PRA has participated in the pivotal or supportive trials that led to U.S. Food and Drug Administration or international regulatory approval of more than 70 drugs. To learn more about PRA, please visit www.prahs.com.
MEDIA INQUIRIES: Christine Rogers, Manager - Public Relations, Corporate Communications EMAIL: [email protected] PHONE: +1 919.786.8463 INVESTOR INQUIRIES: InvestorRelations.prahs.com


Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes
Meta Expands AI Training With Employee Activity Tracking Tools
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 



